Reappraisal of antihypertensive medicine doxazosin and carvedilol as a potential therapeutic for hepatic fibrosis

Yong Han Paik

doi:10.5009/gnl15576

Reappraisal of antihypertensive medicine doxazosin and carvedilol as a potential therapeutic for hepatic fibrosis

Yong Han Paik

Department of Internal Medicine

Research output: Contribution to journal › Editorial

1 Scopus citations

Original language	English
Pages (from-to)	10-11
Number of pages	2
Journal	Gut and Liver
Volume	10
Issue number	1
DOIs	https://doi.org/10.5009/gnl15576
State	Published - Jan 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.5009/gnl15576

Cite this

@article{18fdf58208c04d8aba93318b6fbcbd67,

title = "Reappraisal of antihypertensive medicine doxazosin and carvedilol as a potential therapeutic for hepatic fibrosis",

author = "Paik, \{Yong Han\}",

year = "2016",

month = jan,

doi = "10.5009/gnl15576",

language = "English",

volume = "10",

pages = "10--11",

journal = "Gut and Liver",

issn = "1976-2283",

publisher = "Editorial Office of Gut and Liver",

number = "1",

}

TY - JOUR

T1 - Reappraisal of antihypertensive medicine doxazosin and carvedilol as a potential therapeutic for hepatic fibrosis

AU - Paik, Yong Han

PY - 2016/1

Y1 - 2016/1

UR - https://www.scopus.com/pages/publications/84957309493

U2 - 10.5009/gnl15576

DO - 10.5009/gnl15576

M3 - Editorial

C2 - 26696027

AN - SCOPUS:84957309493

SN - 1976-2283

VL - 10

SP - 10

EP - 11

JO - Gut and Liver

JF - Gut and Liver

IS - 1

ER -

Reappraisal of antihypertensive medicine doxazosin and carvedilol as a potential therapeutic for hepatic fibrosis

UN SDGs

Access to Document

Other files and links

Cite this